2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 63

Identification of Immune Gene Modules in Good Responders to Adalimumab in Rheumatoid Arthritis
Abstract Number: 2082

Identification of Major Clinical Characteristics and Linear Correlations Among DAS28, HAQ and Morning Stiffness Time Using Smart System of Disease Management (SSDM)
Abstract Number: 2063

Identification of Microrna Predictive of Outcome in Lupus Nephritis
Abstract Number: 2121

Identification of microRNA-181a-5p and microRNA-4454 As Mediators of Facet Cartilage Degeneration
Abstract Number: 1961

Identification of Novel Genetic Susceptibility Loci in Primary Antiphospholipid Syndrome
Abstract Number: 2142

Identification of Novel Molecules Targeting Cartilage Aging As Osteoarthritis Therapeutics
Abstract Number: 1217

Identification of Sjogren’s Syndrome-Associated Long Non-Coding RNAs That Are Co-Expressed with Key Protein-Coding Transcripts Involved in Dysregulated Interferon Responses
Abstract Number: 2817

Identification of Subsets of Systemic Lupus Erythematosus Patients By Principal Component Analysis and Urine Biomarkers
Abstract Number: 813

Identifying and Assessing Subgroups in Systemic Sclerosis Patients Based on Comprehensive Autoantibody Profiling
Abstract Number: 427

Identifying Barriers to Zoster Vaccination Rates Among RA Patients in an Academic Rheumatology Practice
Abstract Number: 1061

Identifying Clinical and Epidemiological Risk Factors Associated with Thrombosis and Pregnancy Morbidity in a Large Cohort of Chinese APS Patients
Abstract Number: 2967

Identifying Core Domains for BehçEt’s Syndrome Trials: An International Physician and Patient Delphi Exercise
Abstract Number: 70

Identifying Distal Interactions Between RUNX1 and JIA Associated Single Nucleotide Polymorphisms By Chromosome Conformation Capture
Abstract Number: 2864

Identifying Dysregulated and Co-Dysregulated Markers in Systemic Lupus Erythematosus Using Multi-Modal Biomarker Data from a Large Pre-Clinical Study
Abstract Number: 2461

Identifying Flare in Rheumatoid Arthritis: What Is the Threshold?

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].